Last updated on January 2020

Oral ONC201 in Recurrent GBM H3 K27M Glioma and Midline Glioma


Brief description of study

ONC201 is a new drug candidate that kills cancer cells but not normal cells in laboratory studies and has been previously evaluated in a phase I clinical trial in advanced cancer patients. This clinical trial will enroll patients with recurrent glioblastoma or recurrent WHO Grade IV gliomas with the H3 K27M mutation.

Clinical Study Identifier: NCT02525692

Find a site near you

Start Over

Massachusetts General Hospital

Boston, MA United States
9.4miles
  Connect »